Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:ATCCode |
gptkb:N05CX14
|
| gptkbp:CASNumber |
gptkb:1140077-05-6
|
| gptkbp:controlledSubstanceSchedule |
No
|
| gptkbp:cost |
high
|
| gptkbp:durationOfInfusion |
60 hours
|
| gptkbp:FDAapprovalDate |
2019
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:brexanolone
|
| gptkbp:halfLife |
about 9 hours
|
| gptkbp:hasMolecularFormula |
gptkb:C21H34O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zulresso
|
| gptkbp:indication |
postpartum depression
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sage_Therapeutics
|
| gptkbp:mechanismOfAction |
positive allosteric modulator of GABA-A receptors
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:PubChem_CID |
DB14761
|
| gptkbp:REMSprogram |
Yes
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
dizziness
loss of consciousness sedation dry mouth flushing |
| gptkbp:UNII |
7S5I7G3JQL
|
| gptkbp:bfsParent |
gptkb:Sage_Therapeutics
|
| gptkbp:bfsLayer |
5
|